All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while discount and omega the 3 placebo controls reported either no change or a worsening of symptoms. fatty Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and acids runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the discount treatment. The panel omega seemed to 3 be in agreement that the statistics fatty indicated a significant acids and discount reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied omega five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. 3 The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients fatty treated, bronchospasm did not develop in the second metabisulfite challenge.6

With no acids and discount further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen period in Oregon, Washington and Idaho together omega showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 Patients 3 gave blood serum samples fatty prior to the treatment in 1995 and one year later acids in discount 1996. They were immunoassayed omega for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. 3 For the seasonal fatty allergens reported, the active group (n=27) had on average a greater reduction in IgE than the placebo group (n=34) acids for 13 out of 16 allergens.8

©2003 www.female-prenatal-supplements.com All rights reserved.